FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Bernd Kieseier

Research Profile

Disorders

Chemicals & Drugs

Concepts & Ideas

Anatomy

Procedures

Clinical Trials as Topic

Living Beings

Rats

Co-author Network

Publications

TOP 3
Mark Stettner; Christian Wolf; Kathleen Wolffram; Anne K Mausberg; Thomas Dehmel; Angelika Derksen; Sebastian Heikaus; Bernd C Kieseier
A reliable in vitro model for studying peripheral nerve myelination in mouse.
Bernd C Kieseier; Verena I Leussink; Anne K Mausberg; Marius Ringelstein; Olaf Stüve; Bernd Turowski; Orhan Aktas; Gerald Antoch; Thomas Dehmel; Norbert Goebels; Hans-Peter Hartung
Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses.
Benjamin M Greenberg; Eva Havrdova; Bernhard Hemmer; Bernd C Kieseier; Robert Lisak; Aaron Miller; Michael K Racke; Lawrence Steinman; Olaf Stuve; Heinz Wiendl; Laura J Balcer; Peter A Calabresi; Bruce A C Cree; Anne Cross; Teresa C Frohman; Ralf Gold; Elliot Frohman
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Bernd Kieseier (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Mark Stettner; Christian Wolf; Kathleen Wolffram; Anne K Mausberg; Thomas Dehmel; Angelika Derksen; Sebastian Heikaus; Bernd C Kieseier
A reliable in vitro model for studying peripheral nerve myelination in mouse.
Journal of neuroscience methods 2013;214(1):69-79.
2013: Bernd C Kieseier; Verena I Leussink; Anne K Mausberg; Marius Ringelstein; Olaf Stüve; Bernd Turowski; Orhan Aktas; Gerald Antoch; Thomas Dehmel; Norbert Goebels; Hans-Peter Hartung
Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses.
JAMA neurology 2013;70(3):390-3.
2013: Benjamin M Greenberg; Eva Havrdova; Bernhard Hemmer; Bernd C Kieseier; Robert Lisak; Aaron Miller; Michael K Racke; Lawrence Steinman; Olaf Stuve; Heinz Wiendl; Laura J Balcer; Peter A Calabresi; Bruce A C Cree; Anne Cross; Teresa C Frohman; Ralf Gold; Elliot Frohman
Interferon beta use and disability prevention in relapsing-remitting multiple sclerosis.
JAMA neurology 2013;70(2):248-51.
2013: Anne K Mausberg; Gerd Meyer zu Hörste; Matthias Müller; Mark Stettner; Clemens Warnke; Thomas Dehmel; Mareike Dorok; Hans Peter Hartung; Bernd C Kieseier
Recovery of the T-cell repertoire in CIDP by IV immunoglobulins.
Neurology 2013;80(3):296-303.
2012: Helmar C Lehmann; Richard A C Hughes; Bernd C Kieseier; Hans-Peter Hartung
Recent developments and future directions in Guillain-Barré syndrome.
Journal of the peripheral nervous system : JPNS 2012;17 Suppl 3():57-70.
2012: Sebastian Jander; Bernd C Kieseier; Bernd Turowski; Hans-Peter Hartung
Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod.
Multiple sclerosis (Houndmills, Basingstoke, England) 2012;18(11):1650-2.
2012: Angelika Köhne; Helmar C Lehmann; Mark Stettner; Thomas Dehmel; Hans-Peter Hartung; Parastoo Jangouk; Bernd C Kieseier
Fingolimod impedes Schwann cell-mediated myelination: implications for the treatment of immune neuropathies?
Archives of neurology 2012;69(10):1280-9.
2012: Verena Isabell Leussink; Clemens Warnke; Erasmia Broussalis; Hans-Peter Hartung; Leila Husseini; Bernd C Kieseier
Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity.
Therapeutic advances in neurological disorders 2012;5(5):255-66.
2012: Dirk Mentzer; Jürgen Prestel; Bernd C Kieseier; Wolf-Dieter Ludwig; Ortwin Adams; Ralf Gold; Hans-Peter Hartung; Hartmut Hengel; B Keller-Stanislawski
Case definition for progressive multifocal leukoencephalopathy following treatment with monoclonal antibodies.
Journal of neurology, neurosurgery, and psychiatry 2012;83(9):927-33.
2012: Til Menge; Axel Methner; Andreas Saleh; Tim Waterboer; Orhan Aktas; Achim Berthele; Bruce A C Cree; Hans-Peter Hartung; Bernhard Hemmer; Sudhakar Reddy Kalluri; Bernd C Kieseier
Neuromyelitis optica following human papillomavirus vaccination.
Neurology 2012;79(3):285-7.
2012: Clemens Warnke; Heinz Wiendl; Helena C Kronsbein; Volker Limmroth; Mathias Mäurer; Anita Posevitz-Fejfár; Stephan Schmidt; Florian Seitz; Björn Tackenberg; Ortwin Adams; Achim Berthele; Andrew Chan; Thomas Dehmel; Kathrin Gerbershagen; Ralf Gold; Judith Haas; Hans-Peter Hartung; Bernhard Hemmer; Bernd C Kieseier
Anti-JC-virus antibody prevalence in a German MS cohort.
Multiple sclerosis (Houndmills, Basingstoke, England) 2012;18(7):1054-5.
2012: Bernd C Kieseier; Carlo Pozzilli
Assessing walking disability in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2012;18(7):914-24.
2012: L Husseini; V I Leussink; C Warnke; Hans-Peter Hartung; Bernd C Kieseier
[Cannabinoids for symptomatic therapy of multiple sclerosis].
Der Nervenarzt 2012;83(6):695-704.
2012: Vsevolod Smolianov; Bernd C Kieseier; Thomas Dehmel; Hans Peter Hartung; Bernhard Hemmer; Harald H Hofstetter
Ex vivo activation of naturally occurring IL-17-producing T cells does not require IL-6.
Cytokine 2012;58(2):231-7.
2012: Anke Stroet; Uwe Zettl; Andreas Ziegler; Frauke Zipp; Paul Friedemann; Jan Dörr; Peter Flachenecker; Vinzenz Fleischer; Ralf Gold; Claudia Hemmelmann; Bernd C Kieseier; Holger Nückel; Friedmann Paul; Michaela Starck; Andrew Chan
Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany.
Therapeutic advances in neurological disorders 2012;5(2):75-9.
2012: Bernd C Kieseier; Peter A Calabresi
PEGylation of interferon-β-1a: a promising strategy in multiple sclerosis.
CNS drugs 2012;26(3):205-14.
2012: Per Soelberg Sørensen; Antonio Bertolotto; Gilles Edan; Gavin Giovannoni; Ralf Gold; Eva Havrdova; Ludwig Kappos; Bernd C Kieseier; Xavier Montalban; Tomas Olsson
Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
Multiple sclerosis (Houndmills, Basingstoke, England) 2012;18(2):143-52.
2012: Mark Stettner; Bernd Turowski; Philipp Albrecht; Angelika Derksen; Christian Hartmann; Hans Peter Hartung; Bernd C Kieseier; Eva Neuen-Jacob; Gabriele Arendt
Clinical improvement precedes lesion size regression in a severe case of acute disseminated encephalomyelitis.
BMJ case reports 2012;2012():.
2012: Leila Husseini; Guido Reifenberger; Andreas Saleh; Hans-Peter Hartung; Bernd C Kieseier
Inflammatory demyelinating brain lesions heralding primary CNS lymphoma.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2012;39(1):6-10.
2012: Mark Stettner; Arne Strauss; Bernd C Kieseier; Günter Krämer; Tatjana Kvitkina; Sandra Ohle; Paul Thelen
Long-term antiepileptic treatment with histone deacetylase inhibitors may reduce the risk of prostate cancer.
European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) 2012;21(1):55-64.
2012: Clemens Warnke; Bernd C Kieseier; Verena I Leussink; Orhan Aktas; Alexey Boyko; Norbert Goebels; Hans-Peter Hartung
Cladribine as a therapeutic option in multiple sclerosis.
Clinical immunology (Orlando, Fla.) 2012;142(1):68-75.
2012: Bernd C Kieseier; Helmar C Lehmann; Gerd Meyer Zu Hörste
Autoimmune diseases of the peripheral nervous system.
Autoimmunity reviews 2012;11(3):191-5.
2011: Bernd C Kieseier; Olaf Stüve
Multiple sclerosis: combination therapy in MS--still a valid strategy.
Nature reviews. Neurology 2011;7(12):659-60.
2011: Christian Saure; Thomas Schroeder; Clemens Warnke; Christian Weigelt; Fabian Zohren; Ortwin Adams; Ingmar Bruns; Ron P Cadeddu; Ute Fischer; Hans-Peter Hartung; Bernd C Kieseier; Guido Kobbe; Rainer Haas
Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors.
Archives of neurology 2011;68(11):1428-31.
2011: L Klotz; T Korn; F Zipp; R Gold; B Hemmer; R Hohlfeld; Bernd C Kieseier; Heinz Wiendl
[Diagnosis of multiple sclerosis 2010 revision of the McDonald criteria].
Der Nervenarzt 2011;82(10):1302-9.
2011: C Warnke; Heinz Wiendl; F Zipp; M Stangel; Ortwin Adams; Ralf Gold; Hans-Peter Hartung; Bernhard Hemmer; R Hohlfeld; Bernd C Kieseier
[Risk stratification of progressive multifocal leukoencephalopathy under natalizumab: recommendations for JC virus serology].
Der Nervenarzt 2011;82(10):1314-9.
2011: Mark Stettner; Thomas Dehmel; Angelika Köhne; Anne K Mausberg; Christine R Rose; Bernd C Kieseier
Levetiracetam exhibits protective properties on rat Schwann cells in vitro.
Journal of the peripheral nervous system : JPNS 2011;16(3):250-60.
2011: Hans-Peter Hartung; Bernd C Kieseier; Helmar C Lehmann; Richard A C Hughes
Novel treatment for immune neuropathies on the horizon.
Journal of the peripheral nervous system : JPNS 2011;16(2):75-83.
2011: Bernd C Kieseier
The mechanism of action of interferon-β in relapsing multiple sclerosis.
CNS drugs 2011;25(6):491-502.
2011: Bernd C Kieseier; Heinz Wiendl
Transforming multiple sclerosis trials into practical reality.
Lancet neurology 2011;10(6):493-4.
2011: Bernd C Kieseier; Heinz Wiendl; Hans-Peter Hartung; Verena-Isabell Leussink; Olaf Stüve
Risks and benefits of multiple sclerosis therapies: need for continual assessment?
Current opinion in neurology 2011;24(3):238-43.
2011: João Carlos Correia de Sa; Nikolaos Grigoriadis; Laura Airas; Emmanuel Bartholome; Heinrich Mattle; Celia Oreja-Guevara; Jonathan O'Riordan; Finn Sellebjerg; Bruno Stankoff; Karl Vass; Agata Walczak; Heinz Wiendl; Bernd C Kieseier
Symptomatic therapy in multiple sclerosis: a review for a multimodal approach in clinical practice.
Therapeutic advances in neurological disorders 2011;4(3):139-68.
2011: Christina Boettcher; Clemens Warnke; Stephan Macht; Hans-Peter Hartung; Bernd C Kieseier
An interesting case of nuchal rigidity.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2011;38(3):516-7.
2011: Bernd C Kieseier; Olaf Stüve
A critical appraisal of treatment decisions in multiple sclerosis--old versus new.
Nature reviews. Neurology 2011;7(5):255-62.
2011: Til Menge; Hans-Peter Hartung; Bernd C Kieseier
Neutralizing antibodies in interferon beta treated patients with multiple sclerosis: knowing what to do now : Commentary to: 10.1007/s00415-010-5844-5 "One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients" by S. Malucchi et al.
Journal of neurology 2011;258(5):904-7.
2011: C Warnke; Ortwin Adams; Ralf Gold; Hans-Peter Hartung; R Hohlfeld; Heinz Wiendl; Bernd C Kieseier
[Progressive multifocal leukoencephalopathy under natalizumab. Initial possibilities for risk stratification?].
Der Nervenarzt 2011;82(4):475-80.
2011: Gerd Meyer zu Horste; Timo A Miesbach; Johanna I Muller; Robert Fledrich; Ruth M Stassart; Bernd C Kieseier; Michael P Coleman; Michael W Sereda
The Wlds transgene reduces axon loss in a Charcot-Marie-Tooth disease 1A rat model and nicotinamide delays post-traumatic axonal degeneration.
Neurobiology of disease 2011;42(1):1-8.
2011: Clemens Warnke; Vsevolod Smolianov; Thomas Dehmel; Marcel Andrée; Hartmut Hengel; Fabian Zohren; Gabriele Arendt; Heinz Wiendl; Rainer Haas; Hans-Peter Hartung; Ortwin Adams; Bernd C Kieseier
CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus.
Multiple sclerosis (Houndmills, Basingstoke, England) 2011;17(2):151-6.
2011: O Aktas; J Ingwersen; Bernd C Kieseier; Patrick Küry; R Hohlfeld; Hans-Peter Hartung
[Oral fingolimod in multiple sclerosis: therapeutic modulation of the sphingosine-1-phosphate system].
Der Nervenarzt 2011;82(2):215-25.
2011: Anne K Mausberg; Gerd Meyer zu Hörste; Kazim A Sheikh; Mark Stettner; Thomas Dehmel; Helmar C Lehmann; Bernd C Kieseier
Erythropoietin ameliorates rat experimental autoimmune neuritis by inducing transforming growth factor-β in macrophages.
PloS one 2011;6(10):e26280.
2011: Clemens Warnke; Olaf Stüve; Anna Fogdell-Hahn; Hans-Peter Hartung; Bernd C Kieseier
Critical appraisal of the role of fingolimod in the treatment of multiple sclerosis.
Neuropsychiatric disease and treatment 2011;7():519-27.
2011: Gerd Meyer zu Hörste; Johanna I Müller; Olaf Stüve; Peter Gmeiner; Hans-Peter Hartung; Carsten Korth; Helmar C Lehmann; Stefan Löber; Anne K Mausberg; Bernd C Kieseier
Quinpramine ameliorates rat experimental autoimmune neuritis and redistributes MHC class II molecules.
PloS one 2011;6(6):e21223.
2011: Vsevolod Smolianov; Patrick Vollmar; Bernd C Kieseier; Anne K Mausberg; Thomas Dehmel; Hans P Hartung; Bernhard Hemmer; Harald H Hofstetter
Alteration of T cell cytokine production in PLPp-139-151-induced EAE in SJL mice by an immunostimulatory CpG oligonucleotide.
Journal of neuroinflammation 2011;8():59.
2011: Clemens Warnke; Ortwin Adams; Hans-Peter Hartung; Bernd C Kieseier
Assessment of JC virus DNA in blood and urine from natalizumab-treated patients.
Annals of neurology 2011;69(1):215-6; author reply 216.
2010: C Warnke; V I Leussink; Bernd C Kieseier; Hans-Peter Hartung
[Interferon β for multiple sclerosis. How much is good enough?].
Der Nervenarzt 2010;81(12):1476-82.
2010: Alexander M Herrmann; Kerstin Göbel; Ole J Simon; Nico Melzer; Michael K Schuhmann; Max-Philipp Stenner; Andreas Weishaupt; Christoph Kleinschnitz; Stefan Bittner; Patrick Meuth; Olaf Stuve; Thomas Budde; Bernd C Kieseier; Heinz Wiendl; Sven G Meuth
Glatiramer acetate attenuates pro-inflammatory T cell responses but does not directly protect neurons from inflammatory cell death.
The American journal of pathology 2010;177(6):3051-60.
2010: Olaf Stüve; Bernd C Kieseier; Bernhard Hemmer; Hans-Peter Hartung; Amer Awad; Elliot M Frohman; Benjamin M Greenberg; Michael K Racke; Scott S Zamvil; J Theodore Phillips; Ralf Gold; Andrew Chan; Uwe Zettl; Ron Milo; Ellen Marder; OA Khan; Todd N Eagar
Translational research in neurology and neuroscience 2010: multiple sclerosis.
Archives of neurology 2010;67(11):1307-15.
2010: Sven G Meuth; Stefan Bittner; Jochen C Ulzheimer; Christoph Kleinschnitz; Bernd C Kieseier; Heinz Wiendl
Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of neuroprotective and alternative treatment strategies.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2010;24(5):317-30.
2010: Bernd C Kieseier; Reinhard Hohlfeld
Regulatory T cells in myositis--Good Samaritans at the site of inflammation?
Journal of neuroimmunology 2010;226(1-2):1-2.
2010: Bernd C Kieseier; Douglas R Jeffery
Chemotherapeutics in the treatment of multiple sclerosis.
Therapeutic advances in neurological disorders 2010;3(5):277-91.
2010: Ajith Sominanda; Malin Lundkvist; Anna Fogdell-Hahn; Bernhard Hemmer; Hans-Peter Hartung; Jan Hillert; Til Menge; Bernd C Kieseier
Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta.
Archives of neurology 2010;67(9):1095-101.
2010: Helmar C Lehmann; Hans-Peter Hartung; Bernd C Kieseier; Richard A C Hughes
Guillain-Barré syndrome after exposure to influenza virus.
The Lancet infectious diseases 2010;10(9):643-51.
2010: Bernd C Kieseier; Heinz Wiendl
Postpartum disease activity and breastfeeding in multiple sclerosis revisited.
Neurology 2010;75(5):392-3.
2010: Clemens Warnke; Til Menge; Hans-Peter Hartung; Michael K Racke; Petra D Cravens; Jeffrey Bennett; Elliot M Frohman; Benjamin M Greenberg; Scott S Zamvil; Ralf Gold; Bernhard Hemmer; Bernd C Kieseier; Olaf Stüve
Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided?
Archives of neurology 2010;67(8):923-30.
2010: Jochen C Ulzheimer; Sven G Meuth; Stefan Bittner; Christoph Kleinschnitz; Bernd C Kieseier; Heinz Wiendl
Therapeutic approaches to multiple sclerosis: an update on failed, interrupted, or inconclusive trials of immunomodulatory treatment strategies.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2010;24(4):249-74.
2010: Helmar C Lehmann; F R Hoffmann; Gerd Meyer zu Hörste; Hans-Peter Hartung; Bernd C Kieseier
Central nervous system involvement in patients with monoclonal gammopathy and polyneuropathy.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2010;17(8):1075-81.
2010: Hans-Peter Hartung; Bernd C Kieseier
Atacicept: targeting B cells in multiple sclerosis.
Therapeutic advances in neurological disorders 2010;3(4):205-16.
2010: Christian Wolf; Til Menge; Max-Philipp Stenner; Gerd Meyer zu Hörste; Andreas Saleh; Hans-Peter Hartung; Heinz Wiendl; Bernd C Kieseier
Natalizumab treatment in a patient with chronic inflammatory demyelinating polyneuropathy.
Archives of neurology 2010;67(7):881-3.
2010: Gerd Meyer zu Hörste; Anne K Mausberg; Carsten Korth; Olaf Stüve; Bernd C Kieseier
Quinpramine--a promising compound for treating immune-mediated demyelination of the nervous system.
Drug news & perspectives 2010;23(5):287-94.
2010: Gerd Meyer Zu Hörste; Alla L Zozulya; Houda El-Haddad; Helmar C Lehmann; Hans-Peter Hartung; Heinz Wiendl; Bernd C Kieseier
Active immunization induces toxicity of diphtheria toxin in diphtheria resistant mice--implications for neuroinflammatory models.
Journal of immunological methods 2010;354(1-2):80-4.
2010: Helmar C Lehmann; Parastoo Jangouk; Eva K Kierysch; Gerd Meyer zu Hörste; Hans-Peter Hartung; Bernd C Kieseier
Autoantibody-mediated dysfunction of sympathetic neurons in guillain-barre syndrome.
Archives of neurology 2010;67(2):203-10.
2010: Hans-Peter Hartung; Bernd C Kieseier; O Aktas
[Cladribin. Development of an oral formulation for the treatment of multiple sclerosis].
Der Nervenarzt 2010;81(2):194-202.
2010: L Husseini; V I Leussink; Bernd C Kieseier; Hans-Peter Hartung
[4-Aminopyridine (Fampridine). A new attempt for the symptomatic treatment of multiple sclerosis].
Der Nervenarzt 2010;81(2):203-11.
2010: Gerd Meyer zu Hörste; Holger Heidenreich; Anne K Mausberg; Helmar C Lehmann; Anneloor L M A ten Asbroek; José T Saavedra; Frank Baas; Hans-Peter Hartung; Heinz Wiendl; Bernd C Kieseier
Mouse Schwann cells activate MHC class I and II restricted T-cell responses, but require external peptide processing for MHC class II presentation.
Neurobiology of disease 2010;37(2):483-90.
2010: Clemens Warnke; Heinz Wiendl; Hans-Peter Hartung; Olaf Stüve; Bernd C Kieseier
Identification of targets and new developments in the treatment of multiple sclerosis--focus on cladribine.
Drug design, development and therapy 2010;4():117-26.
2010: Gerd Meyer Zu Horste; Holger Heidenreich; Helmar C Lehmann; Soldano Ferrone; Hans-Peter Hartung; Heinz Wiendl; Bernd C Kieseier
Expression of antigen processing and presenting molecules by Schwann cells in inflammatory neuropathies.
Glia 2010;58(1):80-92.
2009: Clemens Warnke; Ortwin Adams; Bernd C Kieseier
Asymptomatic reactivation of JC virus in patients treated with natalizumab.
The New England journal of medicine 2009;361(25):2489; author reply 2489-90.
2009: Sven G Meuth; Alexander M Herrmann; Ole J Simon; Volker Siffrin; Nico Melzer; Stefan Bittner; Patrick Meuth; Harald F Langer; Stefan Hallermann; Nadia Boldakowa; Josephine Herz; Thomas Munsch; Peter Landgraf; Orhan Aktas; Manfred Heckmann; Volkmar Lessmann; Thomas Budde; Bernd C Kieseier; Frauke Zipp; Heinz Wiendl
Cytotoxic CD8+ T cell-neuron interactions: perforin-dependent electrical silencing precedes but is not causally linked to neuronal cell death.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2009;29(49):15397-409.
2009: Parastoo Jangouk; Thomas Dehmel; Gerd Meyer zu Hörste; Andreas Ludwig; Helmar C Lehmann; Bernd C Kieseier
Involvement of ADAM10 in axonal outgrowth and myelination of the peripheral nerve.
Glia 2009;57(16):1765-74.
2009: Helmar C Lehmann; Bernd C Kieseier
Predicting treatment responses to IV immunoglobulins: can we already ask the genes?
Neurology 2009;73(17):1344-5.
2009: Bernd C Kieseier; Heinz Wiendl; Hans-Peter Hartung; Olaf Stüve
The future of multiple sclerosis therapy.
Pharmacological research : the official journal of the Italian Pharmacological Society 2009;60(4):207-11.
2009: Hans-Peter Hartung; C Warnke; R Hohlfeld; Bernd C Kieseier
[Progressive multifocal leukoencephalopathy. Undesirable side effect of immunotherapy].
Der Nervenarzt 2009;80(10):1143-4, 1146-8, 1150-3.
2009: Til Menge; Nanette C Schloot; M Schott; Bernhard Hemmer; Heinz Wiendl; M Roden; Hans-Peter Hartung; Bernd C Kieseier
Interferon beta treatment does not induce organ-specific autoantibodies in multiple sclerosis.
Neurology 2009;73(11):900-2.
2009: Maria del Pilar Martin; Petra D Cravens; Ryan Winger; Bernd C Kieseier; Sabine Cepok; Todd N Eagar; Scott S Zamvil; Martin S Weber; Elliot M Frohman; Betty K Kleinschmidt-Demasters; Thomas J Montine; Bernhard Hemmer; Christina M Marra; Olaf Stüve
Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.
Archives of neurology 2009;66(8):1016-20.
2009: Gerd Meyer zu Hörste; Jens Reiners; Helmar C Lehmann; Laura Airas; Bernd C Kieseier
CD73 is expressed on invading T lymphocytes in the inflamed peripheral nerve.
Muscle & nerve 2009;40(2):287-9.
2009: Helmar C Lehmann; Gerd Meyer Zu Horste; Bernd C Kieseier; Hans-Peter Hartung
Pathogenesis and treatment of immune-mediated neuropathies.
Therapeutic advances in neurological disorders 2009;2(4):261-81.
2009: C Warnke; Bernd C Kieseier; U Zettl; Hans-Peter Hartung
[Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis].
Der Nervenarzt 2009;80(4):468-74.
2009: Helmar C Lehmann; Angelika Köhne; Fabian Bernal; Parastoo Jangouk; Gerd Meyer zu Hörste; Thomas Dehmel; Hans-Peter Hartung; Stefano C Previtali; Bernd C Kieseier
Matrix metalloproteinase-2 is involved in myelination of dorsal root ganglia neurons.
Glia 2009;57(5):479-89.
2009: T Kopadze; M Döbert; V I Leussink; Thomas Dehmel; Bernd C Kieseier
Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis.
European journal of neurology : the official journal of the European Federation of Neurological Societies 2009;16(3):409-12.
2009: Olaf Stüve; Verena I Leussink; Ruth Fröhlich; Bernhard Hemmer; Hans-Peter Hartung; Til Menge; Bernd C Kieseier
Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis.
Archives of neurology 2009;66(2):259-61.
2009: Franz Fazekas; Bernd C Kieseier
Translating new insights into treatment optimisation in multiple sclerosis.
Journal of the neurological sciences 2009;277 Suppl 1():S1-2.
2009: Michael Karenfort; Bernd C Kieseier; Daniel Tibussek; Birgit Assmann; Joerg Schaper; Ertan Mayatepek
Rituximab as a highly effective treatment in a female adolescent with severe multiple sclerosis.
Developmental medicine and child neurology 2009;51(2):159-61.
2009: Til Menge; H-C Büdingen; Marinos C Dalakas; Bernd C Kieseier; Hans-Peter Hartung
[Targeting B cells in multiple sclerosis. Current concepts and strategies].
Der Nervenarzt 2009;80(2):190-8.
2009: Mahendra P Singh; Gerd Meyer zu Hörste; Wei Hu; Anne K Mausberg; Petra D Cravens; Todd Eagar; Stefan Löber; Ralf Klingenstein; Peter Gmeiner; Carsten Korth; Bernd C Kieseier; Olaf Stüve
Quinpramine is a novel compound effective in ameliorating brain autoimmune disease.
Experimental neurology 2009;215(2):397-400.
2009: Clemens Warnke; Gerd Meyer zu Hörste; Hans-Peter Hartung; Olaf Stüve; Bernd C Kieseier
Review of teriflunomide and its potential in the treatment of multiple sclerosis.
Neuropsychiatric disease and treatment 2009;5():333-40.
2009: Wei Hu; Josbert Metselaar; Li-Hong Ben; Petra D Cravens; Mahendra P Singh; Elliot M Frohman; Todd N Eagar; Michael K Racke; Bernd C Kieseier; Olaf Stüve
PEG minocycline-liposomes ameliorate CNS autoimmune disease.
PloS one 2009;4(1):e4151.
2008: Sven G Meuth; Tatjana Kanyshkov; Nico Melzer; Stefan Bittner; Bernd C Kieseier; Thomas Budde; Heinz Wiendl
Altered neuronal expression of TASK1 and TASK3 potassium channels in rodent and human autoimmune CNS inflammation.
Neuroscience letters 2008;446(2-3):133-8.
2008: Olaf Stüve; Ralf Gold; Andrew Chan; Eilhard Mix; Uwe Zettl; Bernd C Kieseier
alpha4-Integrin antagonism with natalizumab: effects and adverse effects.
Journal of neurology 2008;255 Suppl 6():58-65.
2008: Bernd C Kieseier; Heinz Wiendl; Verena I Leussink; Olaf Stüve
Immunomodulatory treatment strategies in multiple sclerosis.
Journal of neurology 2008;255 Suppl 6():15-21.
2008: Fatima B König; Brigitte Wildemann; Stefan Nessler; Dun Zhou; Bernhard Hemmer; Imke Metz; Hans-Peter Hartung; Bernd C Kieseier; Wolfgang Brück
Persistence of immunopathological and radiological traits in multiple sclerosis.
Archives of neurology 2008;65(11):1527-32.
2008: Anne Waschbisch; Sabine Wintterle; Hanns Lochmüller; Maggie C Walter; Jörg Wischhusen; Bernd C Kieseier; Heinz Wiendl
Human muscle cells express the costimulatory molecule B7-H3, which modulates muscle-immune interactions.
Arthritis and rheumatism 2008;58(11):3600-8.
2008: Ralf A Linker; Bernd C Kieseier; Ralf Gold
Identification and development of new therapeutics for multiple sclerosis.
Trends in pharmacological sciences 2008;29(11):558-65.
2008: Ralf A Linker; Bernd C Kieseier
[Choice of early and escalation treatment options for multiple sclerosis].
Der Nervenarzt 2008;79(10):1123-4,1126-8,1130-2 passim.
2008: Bernd C Kieseier; Gerd Meyer zu Hörste; Helmar C Lehmann; Ralf Gold; Hans-Peter Hartung
Intravenous immunoglobulins in the treatment of immune neuropathies.
Current opinion in neurology 2008;21(5):555-62.
2008: Helmar C Lehmann; Hans-Peter Hartung; Gerd Meyer zu Hörste; Bernd C Kieseier
Plasma exchange in immune-mediated neuropathies.
Current opinion in neurology 2008;21(5):547-54.
2008: Hans-Peter Hartung; Bernd C Kieseier
Advances in biotechnology and novel insights into pathophysiology have contributed to an increased understanding of the pathomechanisms of diseases affecting the peripheral nervous system.
Current opinion in neurology 2008;21(5):517-8.
2008: Verena I Leussink; Helmar C Lehmann; Gerd Meyer zu Hörste; Hans-Peter Hartung; Olaf Stüve; Bernd C Kieseier
Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab. Evidence for disease heterogeneity.
Journal of neurology 2008;255(9):1436-8.
2008: Helmar C Lehmann; Felix R Hoffmann; Andreas Fusshoeller; Gerd Meyer zu Hörste; Rüdiger Hetzel; Hans-Peter Hartung; Michael Schroeter; Bernd C Kieseier
The clinical value of therapeutic plasma exchange in multifocal motor neuropathy.
Journal of the neurological sciences 2008;271(1-2):34-9.
2008: Thomas Dehmel; Hans-Hilmar Goebel; Hans-Peter Hartung; Helmar Lehmann; Heinz Wiendl; Bernd C Kieseier
The metalloproteinase-disintegrin ADAM10 is exclusively expressed by type I muscle fibers.
Muscle & nerve 2008;38(2):1049-51.
2008: Ralf A Linker; Bernd C Kieseier
Innovative monoclonal antibody therapies in multiple sclerosis.
Therapeutic advances in neurological disorders 2008;1(1):43-52.
2008: Verena I Leussink; Helmar C Lehmann; Hans-Peter Hartung; Ralf Gold; Bernd C Kieseier
Type III systemic allergic reaction to natalizumab.
Archives of neurology 2008;65(6):851-2; author reply 852.
2008: Wei Hu; Bernd C Kieseier; Elliot M Frohman; Todd N Eagar; Roger Rosenberg; Hans-Peter Hartung; Olaf Stüve
Prion proteins: physiological functions and role in neurological disorders.
Journal of the neurological sciences 2008;264(1-2):1-8.
2008: Til Menge; Martin S Weber; Bernhard Hemmer; Bernd C Kieseier; Hans-Christian von Büdingen; Clemens Warnke; Scott S Zamvil; Aaron Boster; OA Khan; Hans-Peter Hartung; Olaf Stüve
Disease-modifying agents for multiple sclerosis: recent advances and future prospects.
Drugs 2008;68(17):2445-68.
2008: Olaf Stüve; Jeffrey Bennett; Bernhard Hemmer; Heinz Wiendl; Michael K Racke; Amit Bar-Or; Wei Hu; Robert Zivadinov; Martin S Weber; Scott S Zamvil; Maria F Pacheco; Til Menge; Hans-Peter Hartung; Bernd C Kieseier; Elliot M Frohman
Pharmacological treatment of early multiple sclerosis.
Drugs 2008;68(1):73-83.
2008: Gerd Meyer zu Hörste; Wei Hu; Hans-Peter Hartung; Helmar C Lehmann; Bernd C Kieseier
The immunocompetence of Schwann cells.
Muscle & nerve 2008;37(1):3-13.
2007: Helmar C Lehmann; Angelika Köhne; Gerd Meyer zu Hörste; Bernd C Kieseier
Incidence of Guillain-Barré syndrome in Germany.
Journal of the peripheral nervous system : JPNS 2007;12(4):285.
2007: Christoph Kleinschnitz; Sven G Meuth; Olaf Stüve; Bernd C Kieseier; Heinz Wiendl
Multiple sclerosis therapy: an update on recently finished trials.
Journal of neurology 2007;254(11):1473-90.
2007: Philipp Albrecht; Ruth Fröhlich; Hans-Peter Hartung; Bernd C Kieseier; Axel Methner
Optical coherence tomography measures axonal loss in multiple sclerosis independently of optic neuritis.
Journal of neurology 2007;254(11):1595-6.
2007: Helmar C Lehmann; Hans-Peter Hartung; Bernd C Kieseier
Leopold Ordenstein: on paralysis agitans and multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2007;13(9):1195-9.
2007: T Kopadze; Thomas Dehmel; Heidrun A Mylius; Hans-Peter Hartung; Heinz Wiendl; Bernd C Kieseier
Treosulfan impedes the migration of immunocompetent cells.
Journal of neurology 2007;254(10):1457-8.
2007: Oliver Neuhaus; Bernd C Kieseier; Hans-Peter Hartung
Immunosuppressive agents in multiple sclerosis.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics 2007;4(4):654-60.
2007: Nathaniel F Watson; Douglas Woo; Michael J Doherty; Elliot M Frohman; Michael K Racke; Marc H De Baets; Hans-Peter Hartung; Bernd C Kieseier; Olaf Stüve
Humoral immune responses after rabies infection.
Archives of neurology 2007;64(9):1355-6.
2007: Oliver Neuhaus; Bernd C Kieseier; Hans-Peter Hartung
Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis.
Journal of the neurological sciences 2007;259(1-2):27-37.
2007: Christoph Kleinschnitz; Sven G Meuth; Bernd C Kieseier; Heinz Wiendl
[Update on pathophysiologic and immunotherapeutic approaches for the treatment of multiple sclerosis].
Der Nervenarzt 2007;78(8):883-911.
2007: Hans-P Hartung; Chris H Polman; Antonio Bertolotto; Florian Deisenhammer; Gavin Giovannoni; Eva Havrdova; Bernhard Hemmer; Jan Hillert; Ludwig Kappos; Bernd C Kieseier; Joep Killestein; Christophe Malcus; Manuel Comabella; Andrew R Pachner; Huub Schellekens; Finn Sellebjerg; Krzysztof Selmaj; Per Soelberg Sorensen
Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report.
Journal of neurology 2007;254(7):827-37.
2007: Heinz Wiendl; Bernd C Kieseier; Robert Weissert; Heidrun A Mylius; Uwe Pichlmeier; Hans-Peter Hartung; Arthur Melms; Wilhelm Kuker; Michael Weller
Treatment of active secondary progressive multiple sclerosis with treosulfan.
Journal of neurology 2007;254(7):884-9.
2007: Bernd C Kieseier; Heinz Wiendl; Bernhard Hemmer; Hans-Peter Hartung
Treatment and treatment trials in multiple sclerosis.
Current opinion in neurology 2007;20(3):286-93.
2007: Til Menge; Bernd C Kieseier; Stefan Nessler; Bernhard Hemmer; Hans-Peter Hartung; Olaf Stüve
Acute disseminated encephalomyelitis: an acute hit against the brain.
Current opinion in neurology 2007;20(3):247-54.
2007: Helmar C Lehmann; Angelika Köhne; Gerd Meyer zu Hörste; Thomas Dehmel; Olivia Kiehl; Hans-Peter Hartung; Stefan Kastenbauer; Bernd C Kieseier
Role of nitric oxide as mediator of nerve injury in inflammatory neuropathies.
Journal of neuropathology and experimental neurology 2007;66(4):305-12.
2007: Gerd Meyer zu Hörste; Hans-Peter Hartung; Bernd C Kieseier
From bench to bedside--experimental rationale for immune-specific therapies in the inflamed peripheral nerve.
Nature clinical practice. Neurology 2007;3(4):198-211.
2007: Christoph Kleinschnitz; Sven G Meuth; Bernd C Kieseier; Heinz Wiendl
Immunotherapeutic approaches in MS: update on pathophysiology and emerging agents or strategies 2006.
Endocrine, metabolic & immune disorders drug targets 2007;7(1):35-63.
2007: Thomas Dehmel; Angela Janke; Hans-Peter Hartung; Hans-Hilmar Goebel; Heinz Wiendl; Bernd C Kieseier
The cell-specific expression of metalloproteinase-disintegrins (ADAMs) in inflammatory myopathies.
Neurobiology of disease 2007;25(3):665-74.
2007: Olaf Stüve; Christina M Marra; Petra D Cravens; Mahendra P Singh; Wei Hu; Amy E Lovett-Racke; Nancy L Monson; J Theodore Phillips; Jan W Cohen Tervaert; Richard A Nash; Hans-Peter Hartung; Bernd C Kieseier; Michael M Racke; Elliot M Frohman; Bernhard Hemmer
Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions.
Archives of neurology 2007;64(2):169-76.
2007: Helmar C Lehmann; Hans-Peter Hartung; Gerd R Hetzel; Bernd C Kieseier
[Plasma exchange as a therapeutic option in neurological disorders].
Der Nervenarzt 2007;78(2):166, 168-70, 172-6.
2007: Wei Hu; A Janke; S Ortler; Hans-Peter Hartung; Christoph Leder; Bernd C Kieseier; Heinz Wiendl
Expression of CD28-related costimulatory molecule and its ligand in inflammatory neuropathies.
Neurology 2007;68(4):277-82.
2007: Helmar C Lehmann; Pablo H H Lopez; Gang Zhang; Thien Ngyuen; Jiangyang Zhang; Bernd C Kieseier; Susumu Mori; Kazim A Sheikh
Passive immunization with anti-ganglioside antibodies directly inhibits axon regeneration in an animal model.
The Journal of neuroscience : the official journal of the Society for Neuroscience 2007;27(1):27-34.
2007: Bernd C Kieseier; Heinz Wiendl
Oral disease-modifying treatments for multiple sclerosis: the story so far.
CNS drugs 2007;21(6):483-502.
2007: Bernd C Kieseier; Hans-Peter Hartung
Interferon-beta and neuroprotection in multiple sclerosis--facts, hopes and phantasies.
Experimental neurology 2007;203(1):1-4.
2006: Tea Kopadze; Thomas Dehmel; Hans-Peter Hartung; Olaf Stüve; Bernd C Kieseier
Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis.
Archives of neurology 2006;63(11):1572-8.
2006: Hubertus Köller; Michael Schroeter; Heinrich Feischen; Hans-Peter Hartung; Bernd C Kieseier
Subcutaneous self-infusions of immunoglobulins as a potential therapeutic regimen in immune-mediated neuropathies.
Journal of neurology 2006;253(11):1505-6.
2006: Andrew Chan; Vera Hummel; Franz X Weilbach; Bernd C Kieseier; Ralf Gold
Phagocytosis of apoptotic inflammatory cells downregulates microglial chemoattractive function and migration of encephalitogenic T cells.
Journal of neuroscience research 2006;84(6):1217-24.
2006: Bernd C Kieseier; Hans-Peter Hartung; Heinz Wiendl
Immune circuitry in the peripheral nervous system.
Current opinion in neurology 2006;19(5):437-45.
2006: Bernd C Kieseier; Heinz Wiendl; Hans-Peter Hartung
The inflamed peripheral nervous system: update on immune therapies.
Current opinion in neurology 2006;19(5):433-6.
2006: Heinz Wiendl; Bernd C Kieseier; Ralf Gold; R Hohlfeld; M Bendszus; Hans-Peter Hartung
[Revision of McDonald's new diagnostic criteria for multiple sclerosis].
Der Nervenarzt 2006;77(10):1235, 1237-45.
2006: Ralf Gold; Bernd C Kieseier
Therapy of immune neuropathies with intravenous immunoglobulins.
Journal of neurology 2006;253 Suppl 5():V59-63.
2006: Helmar C Lehmann; Hans-Peter Hartung; Gerd R Hetzel; Olaf Stüve; Bernd C Kieseier
Plasma exchange in neuroimmunological disorders: part 2. Treatment of neuromuscular disorders.
Archives of neurology 2006;63(8):1066-71.
2006: Helmar C Lehmann; Hans-Peter Hartung; Gerd R Hetzel; Olaf Stüve; Bernd C Kieseier
Plasma exchange in neuroimmunological disorders: Part 1: Rationale and treatment of inflammatory central nervous system disorders.
Archives of neurology 2006;63(7):930-5.
2006: Wei Hu; Thomas Dehmel; Jaana Pirhonen; Hans-Peter Hartung; Bernd C Kieseier
Interleukin 23 in acute inflammatory demyelination of the peripheral nerve.
Archives of neurology 2006;63(6):858-64.
2006: Hubertus Köller; Eva Neuen-Jacob; Andreas Saleh; Bernd C Kieseier; S Jander; H-P Hartung
A patient with a benign course of neuromyelitis optica (Devic's syndrome) over 12 years: MRI follow up and histological findings.
Journal of neurology 2006;253(6):819-20.
2006: Bernhard Hemmer; Stefan Nessler; Dun Zhou; Bernd C Kieseier; Hans-Peter Hartung
Immunopathogenesis and immunotherapy of multiple sclerosis.
Nature clinical practice. Neurology 2006;2(4):201-11.
2006: Bernd C Kieseier; Hans-Peter Hartung
Polyneuropathy associated with interferon beta treatment in patients with multiple sclerosis.
Neurology 2006;66(6):955; author reply 955.
2006: Oliver Neuhaus; Bernd C Kieseier; Hans-Peter Hartung
Mitoxantrone in multiple sclerosis.
Advances in neurology 2006;98():293-302.
2006: Bernd C Kieseier; Heinz Wiendl
Multiple sclerosis: advances, excitements, disenchantments.
Lancet neurology 2006;5(1):2-3.
2006: Oliver Neuhaus; Bernd C Kieseier; Hans-Peter Hartung
Therapeutic role of mitoxantrone in multiple sclerosis.
Pharmacology & therapeutics 2006;109(1-2):198-209.
2005: Til Menge; Bernhard Hemmer; Stefan Nessler; Heinz Wiendl; Oliver Neuhaus; Hans-Peter Hartung; Bernd C Kieseier; Olaf Stüve
Acute disseminated encephalomyelitis: an update.
Archives of neurology 2005;62(11):1673-80.
2005: Hans-Peter Hartung; Bernd C Kieseier; Bernhard Hemmer
Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis.
Journal of neurology 2005;252 Suppl 5():v30-7.
2005: Heinz Wiendl; Reinhard Hohlfeld; Bernd C Kieseier
Muscle-derived positive and negative regulators of the immune response.
Current opinion in rheumatology 2005;17(6):714-9.
2005: Oliver Neuhaus; Heinz Wiendl; Bernd C Kieseier; Juan J Archelos; Bernhard Hemmer; Olaf Stüve; Hans-Peter Hartung
Multiple sclerosis: Mitoxantrone promotes differential effects on immunocompetent cells in vitro.
Journal of neuroimmunology 2005;168(1-2):128-37.
2005: Heinz Wiendl; Ute Feger; Michel Mittelbronn; Carolyn Jack; Bettina Schreiner; Christine Stadelmann; Jack Antel; Wolfgang Brueck; Richard Meyermann; Amit Bar-Or; Bernd C Kieseier; Michael Weller
Expression of the immune-tolerogenic major histocompatibility molecule HLA-G in multiple sclerosis: implications for CNS immunity.
Brain : a journal of neurology 2005;128(Pt 11):2689-704.
2005: Olaf Stüve; Sabine Cepok; Birte Elias; Andreas Saleh; Hans-Peter Hartung; Bernhard Hemmer; Bernd C Kieseier
Clinical stabilization and effective B-lymphocyte depletion in the cerebrospinal fluid and peripheral blood of a patient with fulminant relapsing-remitting multiple sclerosis.
Archives of neurology 2005;62(10):1620-3.
2005: Martin Kurz; Heidrun Pischel; Hans-Peter Hartung; Bernd C Kieseier
Tumor necrosis factor-alpha-converting enzyme is expressed in the inflamed peripheral nervous system.
Journal of the peripheral nervous system : JPNS 2005;10(3):311-8.
2005: Frauke Otto; Bernd C Kieseier; Philipp Görtz; H P Hartung; Mario Siebler
The pentapeptide QYNAD does not inhibit neuronal network activity.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques 2005;32(3):344-8.
2005: Bettina Schreiner; Bernd C Kieseier; Hans-Peter Hartung; R Hohlfeld; Heinz Wiendl
[Blocking adhesion molecules with natalizumab in multiple sclerosis].
Der Nervenarzt 2005;76(8):999-1005.
2005: Bernhard Hemmer; Olaf Stüve; Bernd C Kieseier; Huub Schellekens; Hans-Peter Hartung
Immune response to immunotherapy: the role of neutralising antibodies to interferon beta in the treatment of multiple sclerosis.
Lancet neurology 2005;4(7):403-12.
2005: Heinz Wiendl; Reinhard Hohlfeld; Bernd C Kieseier
Immunobiology of muscle: advances in understanding an immunological microenvironment.
Trends in immunology 2005;26(7):373-80.
2005: Hubertus Köller; Michael Schroeter; Bernd C Kieseier; Hans-Peter Hartung
Chronic inflammatory demyelinating polyneuropathy--update on pathogenesis, diagnostic criteria and therapy.
Current opinion in neurology 2005;18(3):273-8.
2005: Bernd C Kieseier; Bernhard Hemmer; Hans-Peter Hartung
Multiple sclerosis--novel insights and new therapeutic strategies.
Current opinion in neurology 2005;18(3):211-20.
2005: Olaf Stüve; Stefan Nessler; Hans-Peter Hartung; Bernhard Hemmer; Heinz Wiendl; Bernd C Kieseier
[Acute disseminated encephalomyelitis. Pathogenesis, diagnosis, treatment, and prognosis].
Der Nervenarzt 2005;76(6):701-7.
2005: Stefan Kastenbauer; Bernd C Kieseier; Bernhard F Becker
No evidence of increased oxidative degradation of urate to allantoin in the CSF and serum of patients with multiple sclerosis.
Journal of neurology 2005;252(5):611-2.
2005: Til Menge; Hans-Christian von Büdingen; Scott S Zamvil; Hans-Peter Hartung; Bernd C Kieseier; Olaf Stüve
[Statins for treatment of CNS diseases. Status report from research and clinical practice].
Der Nervenarzt 2005;76(4):426-37.
2005: Hubertus Köller; Bernd C Kieseier; Sebastian Jander; Hans-Peter Hartung
Chronic inflammatory demyelinating polyneuropathy.
The New England journal of medicine 2005;352(13):1343-56.
2005: Meike Mitsdoerffer; Bettina Schreiner; Bernd C Kieseier; Oliver Neuhaus; Johannes Dichgans; Hans-Peter Hartung; Michael Weller; Heinz Wiendl
Monocyte-derived HLA-G acts as a strong inhibitor of autologous CD4 T cell activation and is upregulated by interferon-beta in vitro and in vivo: rationale for the therapy of multiple sclerosis.
Journal of neuroimmunology 2005;159(1-2):155-64.
2005: Fabian Bernal; Hans-Peter Hartung; Bernd C Kieseier
Tissue mRNA expression in rat of newly described matrix metalloproteinases.
Biological research 2005;38(2-3):267-71.
2004: Bettina Schreiner; Meike Mitsdoerffer; Bernd C Kieseier; Lieping Chen; Hans-Peter Hartung; Michael Weller; Heinz Wiendl
Interferon-beta enhances monocyte and dendritic cell expression of B7-H1 (PD-L1), a strong inhibitor of autologous T-cell activation: relevance for the immune modulatory effect in multiple sclerosis.
Journal of neuroimmunology 2004;155(1-2):172-82.
2004: Oliver Neuhaus; Bernd C Kieseier; Ansgar Klimke; Wolfgang Gaebel; Reinhard Hohlfeld; Hans-Peter Hartung
[Cannabinoids in multiple sclerosis. Opportunity or hazard?].
Der Nervenarzt 2004;75(10):1022-6.
2004: Oliver Neuhaus; Bernd C Kieseier; Hans-Peter Hartung
Mechanisms of mitoxantrone in multiple sclerosis--what is known?
Journal of the neurological sciences 2004;223(1):25-7.
2004: Bernd C Kieseier; Reinhard Kiefer; Ralf Gold; Bernhard Hemmer; Hugh J Willison; Hans-Peter Hartung
Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system.
Muscle & nerve 2004;30(2):131-56.
2004: An D Billiau; Bernd C Kieseier; Hans-Peter Hartung
Biologic role of interferon beta in multiple sclerosis.
Journal of neurology 2004;251 Suppl 2():II10-4.
2004: Heinz Wiendl; H C Lehmann; R Hohlfeld; Hans-Peter Hartung; Bernd C Kieseier
[Multiple sclerosis: potential therapeutic options and update of ongoing studies].
Der Nervenarzt 2004;75(6):536-52.
2004: Bernd C Kieseier; Juan J Archelos; Hans-Peter Hartung
Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases.
Archives of neurology 2004;61(6):929-32.
2004: Oliver Neuhaus; Bernd C Kieseier; Hans-Peter Hartung
Mitoxantrone (Novantrone) in multiple sclerosis: new insights.
Expert review of neurotherapeutics 2004;4(1):17-26.
2003: Wei Hu; Emily Mathey; Hans-Peter Hartung; Bernd C Kieseier
Cyclo-oxygenases and prostaglandins in acute inflammatory demyelination of the peripheral nerve.
Neurology 2003;61(12):1774-9.
2003: Stefan Quasthoff; Christine Pojer; Alexander Mori; Doris Hofer; Peter M Liebmann; Bernd C Kieseier; Wolfgang Schreibmayer
No blocking effects of the pentapeptide QYNAD on Na+ channel subtypes expressed in Xenopus oocytes or action potential conduction in isolated rat sural nerve.
Neuroscience letters 2003;352(2):93-6.
2003: Helmar C Lehmann; Hans-Peter Hartung; Bernd C Kieseier
The prefaces of Charcot: leitmotifs of an international career.
Neurology 2003;61(8):1163; author reply 1163.
2003: Bernd C Kieseier; Ralf Gold; Hans-Peter Hartung
[Mitoxanthrone in the therapy of multiple sclerosis].
Der Nervenarzt 2003;74(10):906-10.
2003: Oliver Neuhaus; Heinz Wiendl; Bernd C Kieseier; Juan J Archelos; Hans-Peter Hartung
[Cholesterol-reducing medications-a new therapeutic option for multiple sclerosis? Statins as immunomodulators].
Der Nervenarzt 2003;74(8):704-7.
2003: Robert Paul; Uwe Koedel; Frank Winkler; Bernd C Kieseier; Adriano Fontana; Manfred Kopf; Hans-Peter Hartung; Hans-Walter Pfister
Lack of IL-6 augments inflammatory response but decreases vascular permeability in bacterial meningitis.
Brain : a journal of neurology 2003;126(Pt 8):1873-82.
2003: Hubertus Köller; Bernd C Kieseier; Sebastian Jander; Hans-Peter Hartung
[Acute and chronic inflammatory neuropathies--therapy].
Deutsche medizinische Wochenschrift (1946) 2003;128(25-26):1405-7.
2003: Hubertus Köller; Bernd C Kieseier; Sebastian Jander; Hans-Peter Hartung
[Acute and chronic inflammatory neuropathies--diagnosis].
Deutsche medizinische Wochenschrift (1946) 2003;128(24):1357-60.
2003: Bernd C Kieseier; Hans-Peter Hartung
Therapeutic strategies in the Guillain-Barré syndrome.
Seminars in neurology 2003;23(2):159-68.
2003: Bernd C Kieseier; Hans-Peter Hartung
Current disease-modifying therapies in multiple sclerosis.
Seminars in neurology 2003;23(2):133-46.
2003: Bernd C Kieseier; Hans-Peter Hartung
Multiple paradigm shifts in multiple sclerosis.
Current opinion in neurology 2003;16(3):247-52.
2003: Bernd C Kieseier; Heidrun Pischel; Eva Neuen-Jacob; Wallace W Tourtellotte; Hans-Peter Hartung
ADAM-10 and ADAM-17 in the inflamed human CNS.
Glia 2003;42(4):398-405.
2003: Bernhard Hemmer; Bernd C Kieseier; Sabine Cepok; Hans-Peter Hartung
New immunopathologic insights into multiple sclerosis.
Current neurology and neuroscience reports 2003;3(3):246-55.
2003: Stefan Kastenbauer; Uwe Koedel; Manfred Wick; Bernd C Kieseier; Hans-Peter Hartung; Hans-Walter Pfister
CSF and serum levels of soluble fractalkine (CX3CL1) in inflammatory diseases of the nervous system.
Journal of neuroimmunology 2003;137(1-2):210-7.
2003: Heinz Wiendl; Bernd C Kieseier
Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies.
Expert opinion on investigational drugs 2003;12(4):689-712.
2003: Angelo Quattrini; Stefano C Previtali; Bernd C Kieseier; Reinhard Kiefer; Giancarlo Comi; Hans-Peter Hartung
Autoimmunity in the peripheral nervous system.
Critical reviews in neurobiology 2003;15(1):1-39.
2002: Bernd C Kieseier; Marinos C Dalakas; Hans-Peter Hartung
Immune mechanisms in chronic inflammatory demyelinating neuropathy.
Neurology 2002;59(12 Suppl 6):S7-12.
2002: Thomas Seifert; Bernd C Kieseier; Stefan Ropele; Siegrid Strasser-Fuchs; F Quehenberger; Franz Fazekas; Hans-Peter Hartung
TACE mRNA expression in peripheral mononudear cells precedes new lesions on MRI in multiple sclerosis.
Multiple sclerosis (Houndmills, Basingstoke, England) 2002;8(6):447-51.
2002: Oliver Neuhaus; Siegrid Strasser-Fuchs; Franz Fazekas; Bernd C Kieseier; Gerald Niederwieser; Hans-Peter Hartung; Juan J Archelos
Statins as immunomodulators: comparison with interferon-beta 1b in MS.
Neurology 2002;59(7):990-7.
2002: Hans-Peter Hartung; Hugh J Willison; Bernd C Kieseier
Acute immunoinflammatory neuropathy: update on Guillain-Barré syndrome.
Current opinion in neurology 2002;15(5):571-7.
2002: Bernd C Kieseier; Marie Tani; Don J Mahad; Nobuyuki Oka; Ho W Tony; Nicola Woodroofe; John W Griffin; Klaus V Toyka; Richard M Ransohoff; Hans-Peter Hartung
Chemokines and chemokine receptors in inflammatory demyelinating neuropathies: a central role for IP-10.
Brain : a journal of neurology 2002;125(Pt 4):823-34.
2002: Reinhard Kiefer; Bernd C Kieseier; Hans-Peter Hartung
Immune-mediated neuropathies.
Advances in neurology 2002;88():111-31.
2001: B Andorfer; Bernd C Kieseier; Emily Mathey; Patricia J Armati; John Pollard; N Oka; Hans-Peter Hartung
Expression and distribution of transcription factor NF-kappaB and inhibitor IkappaB in the inflamed peripheral nervous system.
Journal of neuroimmunology 2001;116(2):226-32.
2001: Reinhard Kiefer; Bernd C Kieseier; G Stoll; H P Hartung
The role of macrophages in immune-mediated damage to the peripheral nervous system.
Progress in neurobiology 2001;64(2):109-27.
2001: Bernd C Kieseier; C Schneider; John M Clements; AJ Gearing; R Gold; Klaus V Toyka; Hans-Peter Hartung
Expression of specific matrix metalloproteinases in inflammatory myopathies.
Brain : a journal of neurology 2001;124(Pt 2):341-51.
2000: Bernd C Kieseier; K Krivacic; S Jung; Heidrun Pischel; Klaus V Toyka; Richard M Ransohoff; Hans-Peter Hartung
Sequential expression of chemokines in experimental autoimmune neuritis.
Journal of neuroimmunology 2000;110(1-2):121-9.
2000: Hans-Peter Hartung; Bernd C Kieseier
The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system.
Journal of neuroimmunology 2000;107(2):140-7.
2000: Bernd C Kieseier; Maria K Storch; Hans-Peter Hartung
Toxic effector molecules in the pathogenesis of immune-mediated disorders of the central nervous system.
Journal of neural transmission. Supplementum 2000;59():69-80.
1999: Bernd C Kieseier; Robert Paul; Uwe Koedel; Thomas Seifert; John M Clements; AJ Gearing; Hans-Walter Pfister; Hans-Peter Hartung
Differential expression of matrix metalloproteinases in bacterial meningitis.
Brain : a journal of neurology 1999;122 ( Pt 8)():1579-87.
1999: Bernd C Kieseier; Thomas Seifert; G Giovannoni; Hans-Peter Hartung
Matrix metalloproteinases in inflammatory demyelination: targets for treatment.
Neurology 1999;53(1):20-5.
1999: Bernd C Kieseier; John M Clements; AJ Gearing; Hans-Peter Hartung
Matrix metalloproteinases exhibit different expression patterns in inflammatory demyelinating diseases of the central and peripheral nervous system.
Annals of the New York Academy of Sciences 1999;878():567-70.
1999: Bernd C Kieseier; Maria K Storch; Juan J Archelos; G Martino; Hans-Peter Hartung
Effector pathways in immune mediated central nervous system demyelination.
Current opinion in neurology 1999;12(3):323-36.
1999: Bernd C Kieseier; Thomas Seifert; Hans-Peter Hartung
[Matrix metalloproteinases. Potential targets for new treatments in inflammatory demyelinating diseases of the nervous system].
Der Nervenarzt 1999;70(6):509-16.
1999: Bernd C Kieseier; G Giovannoni; Hans-Peter Hartung
Immunological surrogate markers of disease activity in multiple sclerosis.
Electroencephalography and clinical neurophysiology. Supplement 1999;50():570-83.
1998: Bernd C Kieseier; John M Clements; Heidrun Pischel; Graham M A Wells; K Miller; AJ Gearing; Hans-Peter Hartung
Matrix metalloproteinases MMP-9 and MMP-7 are expressed in experimental autoimmune neuritis and the Guillain-Barré syndrome.
Annals of neurology 1998;43(4):427-34.
1998: Reinhard Kiefer; Bernd C Kieseier; Wolfgang Brück; Hans-Peter Hartung; Klaus V Toyka
Macrophage differentiation antigens in acute and chronic autoimmune polyneuropathies.
Brain : a journal of neurology 1998;121 ( Pt 3)():469-79.
1998: Bernd C Kieseier; Reinhard Kiefer; John M Clements; K Miller; Graham M A Wells; Tilmann Schweitzer; AJ Gearing; Hans-Peter Hartung
Matrix metalloproteinase-9 and -7 are regulated in experimental autoimmune encephalomyelitis.
Brain : a journal of neurology 1998;121 ( Pt 1)():159-66.
1997: Bernd C Kieseier; Hans-Peter Hartung
Matrix metalloproteinases in experimental autoimmune encephalomyelitis.
Advances in experimental medicine and biology 1997;421():303-6.